GO:0043201 response to L-leucine: Nutrient Sensing Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043201 (response to L-leucine) describes any change in a cell or organism's state or activity caused by an L-leucine stimulus, including movement, secretion, enzyme production and gene expression.
• L-leucine is a branched-chain amino acid that acts as both a nutrient and a signal, triggering rapid secretory and metabolic responses in organisms from yeast to humans [1,3].
• In pancreatic islets, L-leucine directly stimulates insulin and glucagon secretion, and this response is impaired in spontaneously diabetic GK rats [5,7].
• L-leucine also regulates protein turnover: it promotes muscle protein synthesis and suppresses breakdown through mTORC1-dependent signalling in humans.
• Beyond metabolism, L-leucine influences mitochondrial outer-membrane protein stability and respiration adaptation, linking nutrient sensing to organelle quality control.
• The response to L-leucine is conserved across evolution, with fission yeast Schizosaccharomyces pombe using leucine as a key nitrogen and metabolic signal.
Description
GO:0043201, response to L-leucine, is a Gene Ontology biological process term that captures any change in the state or activity of a cell or organism as a result of an L-leucine stimulus. L-leucine is one of the three branched-chain amino acids and is unique among nutrients because it serves both as a building block for protein synthesis and as a potent signalling molecule. The term encompasses a wide range of downstream outputs, including changes in movement, secretion, enzyme production and gene expression. Researchers study this process because it sits at the intersection of nutrient sensing, metabolic regulation and cell-fate decisions, and because its dysregulation is linked to diabetes, muscle wasting and mitochondrial dysfunction [2,3,5]. The response to L-leucine is evolutionarily ancient. In the fission yeast Schizosaccharomyces pombe, leucine availability controls metabolic and transcriptional programmes that allow adaptation to nitrogen source quality. In bacteria such as Bacillus velezensis, D- and L-leucine modulate genome-wide transcription and secondary metabolite production, including surfactin biosynthesis. In mammals, L-leucine is a well-characterized secretagogue in pancreatic islets, where it induces glucagon and insulin release in a dose-dependent manner. The same amino acid also regulates whole-body protein turnover, as shown by leucine turnover studies during starvation. Because L-leucine couples nutrient availability to cell behaviour, GO:0043201 is a focal point for understanding how cells integrate metabolic signals. The process is not a single linear pathway but a network of sensing, signalling and effector modules that differ by cell type and organism [1,2,3]. This article synthesizes the authoritative GO definition with verified experimental literature to describe the mechanisms, key genes, disease relevance and research methods associated with response to L-leucine.
response to L-leucine At A Glance
| GO ID | GO:0043201 |
|---|---|
| GO term | response to L-leucine |
| Ontology | biological_process |
| Synonym | response to leucine |
| Definition | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a L-leucine stimulus. |
| Major function | Nutrient sensing and signal transduction that converts L-leucine availability into changes in secretion, enzyme production, gene expression and metabolism. |
| Taxonomic scope | Conserved from bacteria and fungi to mammals, including Bacillus velezensis, Schizosaccharomyces pombe, rodents and humans [1,4,5,7]. |
| Key physiological outputs | Insulin and glucagon secretion, muscle protein synthesis and breakdown, mitochondrial respiration adaptation, and transcriptional reprogramming [2,3,5,7]. |
| Disease relevance | Type 2 diabetes, muscle wasting, mitochondrial dysfunction and neuronal ceroid lipofuscinoses [2,3,5,8]. |
What Is GO:0043201?
In simple terms, GO:0043201 describes everything a cell or organism does differently after it encounters L-leucine. The official QuickGO definition states: Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a L-leucine stimulus. This means the term is deliberately broad: it includes rapid events such as hormone secretion, slower events such as changes in gene transcription, and adaptive events such as altered enzyme activity or mitochondrial function [1,2,7]. It is a biological process term, not a molecular function or cellular component term, and its synonym is response to leucine.
Why Is response to L-leucine Important in Cell Biology?
Response to L-leucine matters because L-leucine is one of the most potent nutrient signals in mammalian physiology, and its sensing pathways are directly tied to diseases of metabolism, muscle and the nervous system [3,5,8]. Defects in leucine-stimulated insulin secretion contribute to beta-cell dysfunction in type 2 diabetes, while leucine resistance contributes to anabolic resistance in aging muscle [3,5]. In mitochondria, leucine availability controls the stability of outer-membrane proteins and respiratory adaptation, connecting amino acid sensing to organelle quality control. In rare neurodegenerative disorders such as CLN1 disease, leucine-based compounds have been tested as therapeutics, although efficacy in mouse models has been limited. Understanding GO:0043201 therefore provides a mechanistic framework for metabolic disease research, muscle biology and neurotherapeutics.
• L-leucine is a direct secretagogue for insulin and glucagon in pancreatic islets, making GO:0043201 central to glucose homeostasis research.
• Impaired islet response to L-leucine is a feature of spontaneously diabetic GK rats, linking the term to type 2 diabetes pathophysiology.
• L-leucine stimulates muscle protein synthesis and suppresses muscle protein breakdown via mTORC1-dependent signalling in humans.
• Leucine inhibits degradation of outer mitochondrial membrane proteins, adapting mitochondrial respiration to nutrient status.
• Starvation alters leucine turnover and the metabolic response to leucine, showing that whole-body leucine handling is physiologically regulated.
• In fission yeast, leucine elicits conserved transcriptional and metabolic responses that serve as a model for nutrient sensing.
• In Bacillus velezensis, D- and L-leucine reprogram transcription and affect surfactin production, linking the term to microbial biotechnology.
• N-acetyl-L-leucine has been evaluated in CLN1 disease models, connecting leucine biology to neurodegeneration research.
• The term spans secretion, enzyme production and gene expression, making it a multi-output process suitable for systems-level studies [1,2,3].
• Because the response is conserved, findings in yeast and bacteria can inform hypotheses about mammalian leucine sensing [1,4].
What Happens During response to L-leucine?
L-leucine sensing and uptake
In simple terms: The cell first has to notice that L-leucine is present and bring it inside or detect it at the surface.
The response to L-leucine begins with sensing and transport. In pancreatic islets, L-leucine is taken up and metabolized, which generates signals that trigger secretion. In fission yeast, leucine availability is sensed as a nitrogen and metabolic cue that reshapes global gene expression. In bacteria such as Bacillus velezensis, both D- and L-leucine are detected and elicit genome-wide transcriptional changes. These sensing steps are the entry point for GO:0043201 and determine the magnitude and duration of downstream outputs.
Secretory and metabolic responses
In simple terms: Once sensed, L-leucine causes cells to release hormones and adjust their metabolism.
A hallmark of the L-leucine response in mammals is secretion. L-leucine induces glucagon and insulin release from pancreatic islets in vitro, with a characteristic off-response when the stimulus is removed. This secretory response is impaired in spontaneously diabetic GK rats, where enzymatic and metabolic data indicate decreased islet responsiveness to L-leucine. In humans, leucine also modulates muscle protein turnover, increasing synthesis and decreasing breakdown through coordinated metabolic signalling. These secretory and metabolic outputs are core measurable phenotypes of GO:0043201.
Transcriptional and translational reprogramming
In simple terms: L-leucine changes which genes are turned on and how much protein is made.
L-leucine alters gene expression programmes across organisms. In Schizosaccharomyces pombe, leucine elicits a defined transcriptional response that supports adaptation to changing nitrogen conditions. In Bacillus velezensis BS-37, genome and transcriptome analysis revealed that D- and L-leucine reprogram gene expression in ways that affect surfactin production from glycerol. In mammalian muscle, leucine promotes protein synthesis and suppresses breakdown, reflecting translational and proteolytic reprogramming. These changes in gene expression and enzyme production are explicitly covered by the GO definition [1,3,4].
Mitochondrial adaptation and protein stability
In simple terms: L-leucine helps mitochondria adjust their respiration by protecting certain outer-membrane proteins from degradation.
Recent work shows that leucine inhibits the degradation of outer mitochondrial membrane proteins, thereby adapting mitochondrial respiration. This links amino acid availability to mitochondrial proteostasis and respiratory capacity. The mechanism involves leucine-dependent stabilization of outer-membrane proteins, which in turn supports respiratory adaptation under changing nutrient conditions. This subsection illustrates how GO:0043201 extends beyond classical secretion to organelle-level quality control.
Whole-body turnover and starvation responses
In simple terms: The body's handling of L-leucine changes with feeding state, especially during starvation.
Leucine turnover and the metabolic response to leucine are not fixed; they change with nutritional state. In humans, starvation alters leucine turnover and the metabolic response to leucine, indicating that whole-body leucine handling is dynamically regulated. This systemic dimension is important because GO:0043201 can be studied at the organism level as well as the cellular level. Together with tissue-specific responses in islets and muscle, these findings show that the L-leucine response is context-dependent [3,5,6].
Key Genes Involved in GO:0043201 response to L-leucine
The genes and proteins below are experimentally implicated in response to L-leucine across yeast, bacteria, rodents and humans, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| mTORC1 pathway components | Central kinase complex integrating leucine availability to promote protein synthesis and suppress breakdown | Key readout for muscle protein turnover studies in humans |
| Insulin (INS) | Hormone secreted in response to L-leucine from pancreatic beta cells | Direct measure of leucine-stimulated secretion in islets |
| Glucagon (GCG) | Hormone secreted in response to L-leucine from pancreatic alpha cells | Characterizes the dynamics of L-leucine-induced secretion |
| Mitochondrial outer membrane proteins | Stabilized by leucine to adapt mitochondrial respiration | Links leucine sensing to mitochondrial proteostasis |
| Schizosaccharomyces pombe leucine-responsive genes | Mediate transcriptional adaptation to leucine as a nitrogen cue | Model for conserved nutrient sensing |
| Bacillus velezensis BS-37 transcriptional regulators | Reprogram gene expression in response to D-/L-leucine | Biotechnological model for surfactin production |
| Pancreatic islet metabolic enzymes | Support leucine metabolism and secretory coupling | Enzymatic and metabolic data in diabetic GK rats |
| Whole-body leucine turnover machinery | Regulates leucine flux during feeding and starvation | Human starvation studies of leucine turnover |
| CLN1/PPT1 pathway | Neuronal ceroid lipofuscinosis pathway targeted by N-acetyl-L-leucine | Mouse model of CLN1 disease for therapeutic testing |
| Branched-chain amino acid transaminases | Initiate leucine catabolism and signalling metabolite production | Implicated in islet and muscle leucine responses [3,5] |
| Branched-chain alpha-ketoacid dehydrogenase complex | Oxidizes leucine-derived ketoacids | Metabolic node in leucine-stimulated secretion |
| Amino acid transporters | Mediate L-leucine uptake into cells | Required for sensing and downstream responses [1,7] |
| Mitochondrial respiratory chain components | Execute respiration adaptation downstream of leucine | Functional readout of leucine-dependent mitochondrial adaptation |
| Surfactin biosynthesis genes | Secondary metabolite production modulated by leucine | Bacillus velezensis BS-37 bioprocess studies |
| Nitrogen-responsive transcription factors in yeast | Regulate leucine-dependent gene expression | Fission yeast response to leucine |
| Muscle proteolysis machinery | Suppressed by leucine to reduce protein breakdown | Human muscle protein breakdown studies |
How Is response to L-leucine Regulated?
The response to L-leucine is regulated at multiple levels. In mammals, the mTORC1 pathway integrates leucine availability to control protein synthesis and breakdown, making it a central regulatory node. In pancreatic islets, leucine metabolism and secretory coupling determine the magnitude of insulin and glucagon release, and this regulation is impaired in diabetic GK rats. In fission yeast, leucine acts as a nitrogen signal that regulates transcriptional programmes. In mitochondria, leucine availability regulates the stability of outer-membrane proteins, thereby tuning respiration. Whole-body leucine turnover is further modulated by nutritional state such as starvation. Together, these layers create a context-dependent regulatory network that defines GO:0043201.
response to L-leucine and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| Insulin (INS) | Type 2 diabetes / impaired leucine-stimulated insulin secretion | Pancreatic islet KO or point-mutation models [5,7] |
| Glucagon (GCG) | Dysregulated glucagon secretion in diabetes | Alpha-cell-specific knockout models |
| mTORC1 pathway components | Muscle wasting / anabolic resistance | Muscle-specific knockout or knock-in models |
| Mitochondrial outer membrane proteins | Mitochondrial dysfunction / respiration adaptation | Tagged knock-in for stability assays |
| CLN1/PPT1 | Neuronal ceroid lipofuscinosis (CLN1 disease) | CLN1 mouse model treated with N-acetyl-L-leucine |
Type 2 diabetes and islet dysfunction
The response to L-leucine is directly relevant to type 2 diabetes because L-leucine stimulates insulin and glucagon secretion from pancreatic islets. In spontaneously diabetic GK rats, the pancreatic islet response to L-leucine is decreased, with enzymatic, metabolic and secretory data indicating impaired leucine sensing. This makes leucine-stimulated secretion a functional readout for beta-cell dysfunction and a potential target for therapeutic strategies aimed at preserving islet responsiveness [5,7].
Muscle wasting and anabolic resistance
L-leucine is a potent anabolic signal in skeletal muscle, promoting muscle protein synthesis and suppressing muscle protein breakdown through associated molecular signalling responses. When this response is blunted, as in aging or catabolic illness, anabolic resistance contributes to muscle wasting. Studying GO:0043201 in muscle therefore informs nutritional and pharmacological approaches to maintain muscle mass.
Mitochondrial dysfunction
Leucine inhibits degradation of outer mitochondrial membrane proteins to adapt mitochondrial respiration. This places the L-leucine response at the center of mitochondrial quality control. Dysregulation of this process could contribute to mitochondrial dysfunction in metabolic and degenerative diseases, making it a target for mechanistic studies.
Neurodegeneration and CLN1 disease
N-acetyl-L-leucine has been tested as a therapeutic in a mouse model of CLN1 disease, a neuronal ceroid lipofuscinosis, but showed limited therapeutic efficacy. This negative result is important because it highlights the need for rigorous preclinical testing of leucine-based compounds in neurodegeneration and underscores the complexity of translating leucine biology into therapy.
From response to L-leucine-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate gene mediate leucine-stimulated insulin secretion? | Knockout of the gene in pancreatic beta cells followed by L-leucine stimulation [5,7] |
| Does a specific amino acid substitution alter leucine sensing? | Point-mutation knock-in of the candidate residue [2,3] |
| Where is the leucine-responsive protein localized? | Tagged knock-in with fluorescent or epitope tag |
| Does overexpression of a leucine-responsive gene enhance the response? | Overexpression cell model treated with L-leucine [1,3] |
| Which genes are required for leucine-dependent transcriptional reprogramming? | CRISPR library screening in yeast or mammalian cells [1,4] |
| Does leucine protect mitochondrial outer-membrane proteins from degradation? | Knockout or tagged knock-in of outer-membrane proteins plus leucine treatment |
How to Study the response to L-leucine Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Genome-wide transcript changes | Identifying leucine-responsive gene programmes [1,4] |
| Secretion assays | Hormone release dynamics | Measuring L-leucine-induced insulin and glucagon secretion [5,7] |
| Stable isotope tracers | Protein synthesis and breakdown rates | Muscle protein turnover in humans |
| Leucine turnover studies | Whole-body leucine flux | Starvation and feeding state experiments |
| Protein stability assays | Degradation of outer mitochondrial membrane proteins | Mitochondrial adaptation studies |
| Respiration measurements | Mitochondrial respiratory capacity | Functional readout of leucine-dependent adaptation |
| CRISPR library screening | Gene requirements for leucine response | Discovery of novel regulators [1,4] |
| Immunoblotting | Signalling pathway activation | mTORC1 and related pathways |
Transcriptomics and RNA-seq
RNA-seq is widely used to capture the gene expression changes that define GO:0043201. In Schizosaccharomyces pombe, transcriptomic analysis revealed the leucine-responsive gene programme. In Bacillus velezensis BS-37, genome and transcriptome analysis showed how D- and L-leucine reprogram transcription, including effects on surfactin production. These approaches identify the effector genes downstream of leucine sensing and can be combined with CRISPR perturbations to establish causality [1,4].
Secretion assays and islet physiology
Because L-leucine is a secretagogue, secretion assays are central to studying GO:0043201. L-leucine-induced glucagon and insulin secretion and the off-response have been characterized in vitro using dynamic secretion measurements. Islet enzymatic, metabolic and secretory data from diabetic GK rats demonstrate how secretion assays can reveal disease-related defects in leucine responsiveness. These methods provide quantitative, time-resolved readouts of the process [5,7].
Protein turnover and signalling analysis
Muscle protein synthesis and breakdown can be measured using stable isotope tracer methods, and associated molecular signalling responses can be assessed by immunoblotting for mTORC1 pathway components. Whole-body leucine turnover studies during starvation provide complementary information on systemic leucine handling. Together, these methods connect molecular signalling to physiological outcomes [3,6].
Mitochondrial proteostasis and respiration assays
To study the mitochondrial arm of the L-leucine response, researchers measure outer mitochondrial membrane protein stability and respiration. Leucine inhibits degradation of outer mitochondrial membrane proteins to adapt mitochondrial respiration, which can be assayed using protein stability assays and respiratory measurements. These methods link nutrient sensing to organelle function and are suitable for knockout and tagged knock-in models.
How CRISPR Can Be Used to Study GO:0043201 response to L-leucine
Knockout
CRISPR knockout is used to test whether a candidate gene is required for the response to L-leucine. For example, knocking out genes involved in islet leucine sensing can reveal their contribution to insulin or glucagon secretion [5,7]. In yeast and bacteria, knockout or deletion libraries help identify genes needed for leucine-dependent transcriptional reprogramming [1,4]. Knockout models are also useful for testing whether mitochondrial outer-membrane proteins are necessary for leucine-dependent respiration adaptation.
Point Mutation
Point-mutation models allow precise testing of residues that mediate leucine sensing or signalling. For instance, mutating phosphorylation or binding sites in mTORC1 pathway components can reveal how leucine signals are transmitted. In mitochondrial outer-membrane proteins, point mutations can identify domains required for leucine-dependent stabilization. These models are essential for distinguishing correlation from causation in GO:0043201 research.
Knock-in
Knock-in models are used to tag or replace endogenous genes with reporters or disease-relevant variants. Tagged knock-in of mitochondrial outer-membrane proteins enables direct measurement of their stability in response to leucine. Knock-in of disease-associated variants in islet or muscle genes can model altered leucine responsiveness [3,5]. These models preserve endogenous regulation and are therefore well suited for physiological studies of GO:0043201.
Overexpression
Overexpression models test whether increasing the level of a leucine-responsive gene enhances or sustains the response. Overexpressing candidate regulators in yeast or mammalian cells followed by L-leucine treatment can reveal gain-of-function effects on transcription, secretion or metabolism [1,3]. Overexpression is also useful for producing sufficient protein for biochemical assays of leucine-dependent interactions.
How EDITGENE Supports response to L-leucine Research
Researchers studying response to L-leucine-related genes often need to determine whether a candidate gene is causally involved in sensing, secretion, transcriptional reprogramming or mitochondrial adaptation. Establishing causality requires precise genome engineering, because pharmacological or overexpression approaches alone cannot distinguish direct effects from secondary adaptations. EDITGENE provides the CRISPR tools and models needed to move from correlation to mechanism in GO:0043201 research.
Contact EDITGENE today to design your custom CRISPR model for response to L-leucine research.
Frequently Asked Questions About response to L-leucine
What is GO:0043201 response to L-leucine?
GO:0043201 is a Gene Ontology biological process term defined as any process that results in a change in state or activity of a cell or an organism as a result of an L-leucine stimulus, including changes in movement, secretion, enzyme production and gene expression.
What genes are involved in response to L-leucine?
Genes and pathways implicated include mTORC1 pathway components, insulin and glucagon, mitochondrial outer membrane proteins, branched-chain amino acid metabolic enzymes and leucine-responsive transcriptional regulators in yeast and bacteria [1,2,3,4,5,7].
How does L-leucine stimulate insulin secretion?
L-leucine is taken up and metabolized by pancreatic islets, generating signals that trigger insulin and glucagon release; this response has been characterized in vitro and is impaired in diabetic GK rats [5,7].
Is the response to L-leucine conserved across species?
Yes. Leucine responses have been documented in bacteria such as Bacillus velezensis, fission yeast Schizosaccharomyces pombe, rodents and humans, indicating deep evolutionary conservation [1,4,5,7].
What is the role of L-leucine in muscle protein synthesis?
L-leucine promotes muscle protein synthesis and suppresses muscle protein breakdown through associated molecular signalling responses, as reviewed in human studies.
How does leucine affect mitochondria?
Leucine inhibits degradation of outer mitochondrial membrane proteins to adapt mitochondrial respiration, linking nutrient sensing to mitochondrial proteostasis.
Does starvation change the response to L-leucine?
Yes. Starvation alters leucine turnover and the metabolic response to leucine, showing that whole-body leucine handling is nutritionally regulated.
Is N-acetyl-L-leucine effective for CLN1 disease?
In a mouse model of CLN1 disease, N-acetyl-L-leucine showed limited therapeutic efficacy, highlighting the need for further preclinical evaluation.
What methods are used to study response to L-leucine?
Common methods include RNA-seq, secretion assays, stable isotope tracers, leucine turnover studies, protein stability assays, respiration measurements and CRISPR screening [1,2,3,4,5,6,7].
How can CRISPR help study GO:0043201?
CRISPR knockout, point mutation, knock-in and overexpression models allow causal testing of candidate genes in leucine sensing, secretion, transcription and mitochondrial adaptation [1,2,3,5].
Conclusion
GO:0043201 response to L-leucine is a broad but mechanistically rich biological process that connects nutrient sensing to secretion, gene expression, protein turnover and mitochondrial function [1,2,3,7]. Its relevance spans type 2 diabetes, muscle wasting, mitochondrial dysfunction and neurodegeneration, making it a high-value target for both basic and translational research [2,3,5,8]. Because the response is conserved from bacteria to humans, findings across model systems can inform one another and accelerate discovery [1,4]. Precise genome engineering is essential for establishing causality in this field. By combining knockout, point-mutation, knock-in, overexpression and CRISPR screening approaches with bioinformatics, researchers can dissect the regulatory network underlying the L-leucine response and identify actionable therapeutic nodes [1,2,3,5].
References
- 1. Ohtsuka H et al.. 2022. Response to leucine in Schizosaccharomyces pombe (fission yeast).. FEMS Yeast Res 22(1) PMID: 35325114
- 2. Li Q et al.. 2025. Leucine inhibits degradation of outer mitochondrial membrane proteins to adapt mitochondrial respiration.. Nat Cell Biol 27(11):1889-1901 PMID: 41174002
- 3. Kaspy MS et al.. 2024. The effects of branched-chain amino acids on muscle protein synthesis, muscle protein breakdown and associated molecular signalling responses in humans: an update.. Nutr Res Rev 37(2):273-286 PMID: 37681443
- 4. Zhou D et al.. 2019. Genome and transcriptome analysis of Bacillus velezensis BS-37, an efficient surfactin producer from glycerol, in response to d-/l-leucine.. Microbiologyopen 8(8):e00794 PMID: 30793535
- 5. Giroix MH et al.. 1999. Decreased pancreatic islet response to L-leucine in the spontaneously diabetic GK rat: enzymatic, metabolic and secretory data.. Diabetologia 42(8):965-77 PMID: 10491757
- 6. Sherwin RS. 1978. Effect of starvation on the turnover and metabolic response to leucine.. J Clin Invest 61(6):1471-81 PMID: 659610
- 7. Pek S et al.. 1978. L-Leucine-induced secretion of glucagon and insulin, and the "off-response" to L-leucine in vitro. I. Characterization of the dynamics of secretion.. Endocrinology 103(4):1208-18 PMID: 744140
- 8. Ziółkowska EA et al.. 2025. Limited therapeutic efficacy of N-acetyl-L-leucine in a mouse model of CLN1 disease.. Sci Rep 16(1):3033 PMID: 41466111
